Pyro70 wrote:[rp1954]... could you clarify what you mean by “immunochemo”?
My previous discussion
Do you also have research paper backing it’s efficacy?
This arises out of many papers from several lines of research and clinical treatment in Japan and the US, leading to the core immunochemo treatments that are substantially documented:ADAPT
(an oral 5FU derivative) + celecoxib
, developed in the US, and UFT based (an oral 5FU derivative from Asia)
immunochemo from Japan, UFT + PSK +- cimetidine
Basically, by the 1980s, Japanese drs observed that milder, lower dose, daily 5FU could produce responses or longer OS in patients previously failed by heavy duty 5FU cycles. This was also true of nicer UFT, introduced in the 1980s. This is called metronomic chemo. Sometimes US doctors in the 1980s/90s suggested that their mCRC friends get on a plane and go to a country that used UFT.
There are a number of papers from Japan that showed efficacy with UFT or oral 5FU, combined with PSK and/or cimetidine, in various stage 4 GI cancers, and refractory case histories. The trial paper that I consider most important is Matsumoto (2002)
, where daily, oral 5FU+cimetidine showed incremental numerical superiority to Folfox in stage 2 and 3 patients, specifically those patients with raised tissue markers for CA199 and CSLEX1 (about 65% of their patients).
Likewise, there are papers where ADAPT showed hell on wheels superiority for stage 4 and mCRC recurs, with good results generally, and some types of patients living many years longer with much better quality of life.
Life Extension Foundation has had its own articles with references about immune enhancing treatments for cancer, surgery, and CRC, specifically.
We combined these and other enhancements in a logical manner to stop metastasis, increase immunochemo intensity, and personal efficacy. Also I worked to ensure that we could track efficacy on an individual patient basis by sequential patient preparation, bloodwork, scans, patient observation and QoL, and surgical biopsy.